Thomas is a toxicologic, experimental and comparative pathologist with over 30 years of experience. Thomas started his career as a diagnostician and research immuno-pathologist in the United States and received his PhD from Louisiana State University in 2000. He then joined the biopharmaceutical industry in Europe as a research and regulatory safety pathologist in Servier then Eli Lilly & Company. Thomas moved to contract research organizations in 2007 to develop tissue cross reactivity and immunohistochemistry/in situ hybridization assays and has contributed to over hundreds of studies. Thomas is currently embracing and leading the digital revolution in pathology at StageBio and is specialized in in situ molecular techniques and investigative/efficacy studies in animal models out of TPL Path Labs GmbH, a StageBio company, based in Freiburg, Germany. Thomas helps clients design the best possible clinical and non-clinical efficacy or safety investigative studies and is leading implementation of in situ molecular assays and quantitative pathology projects with specialized image analysis, along with performing pathology evaluations.